New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
05:49 EDTTEVASynthon says glatiramer shows equivalence to Teva's Copaxone
Synthon announced that the companyís glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple sclerosis. The Phase III Glatiramer Acetate clinical trial to assess equivalence with Teva's (TEVA) Copaxone is to-date the only Phase III study conducted with a generic version of Copaxone and has demonstrated an equivalent efficacy and safety profile for Synthonís glatiramer acetate compared to Copaxone, Synthon said. Synthon has already submitted an Abbreviated New Drug Application for glatiramer acetate for injection in pre-filled syringes to the FDA in November 2011.
News For TEVA From The Last 14 Days
Check below for free stories on TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:19 EDTTEVAUBS to hold a field trip
Subscribe for More Information
05:26 EDTTEVAProtalix appoints Moshe Manor as CEO
Subscribe for More Information
September 17, 2014
11:01 EDTTEVAActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use